Aclaris Therapeutics (ACRS) Total Non-Current Liabilities (2016 - 2026)

Aclaris Therapeutics' Total Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $53.7 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 7.91% year-over-year to $53.7 million in Q1 2026; TTM through Mar 2026 was $53.7 million, a 7.91% increase from a year earlier, with the FY2025 full-year figure at $46.4 million, down 23.13% from the prior year.
• Total Non-Current Liabilities advanced to $53.7 million in Q1 2026 per ACRS's latest filing, from $46.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $60.3 million in Q4 2024 and bottomed at $18.0 million in Q2 2024.
• The 5-year median for Total Non-Current Liabilities is $37.2 million (2023), against an average of $37.0 million.
• Across the five-year window, Total Non-Current Liabilities tumbled 64.1% in 2022 and jumped 207.81% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $23.9 million in 2022, then surged by 55.61% to $37.2 million in 2023, then jumped by 62.4% to $60.3 million in 2024, then dropped by 23.13% to $46.4 million in 2025, then advanced by 15.69% to $53.7 million in 2026.
• Per Business Quant, the three latest ACRS Total Non-Current Liabilities figures stand at $53.7 million (Q1 2026), $46.4 million (Q4 2025), and $53.7 million (Q3 2025).